Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Addison’s Disease in 10 Major Markets
Addison's disease (AD) is a chronic and rare endocrinal disorder, caused by destruction of the adrenal cortex which leads to the reduced production of glucocorticoids, mineralocorticoids and adrenal androgens. Chronic adrenal insufficiency and hypersecretion of ACTH is representative of the basic clinical signs and symptoms. AD can be part of the autoimmune polyglandular syndrome (PAS) (type 1 and 2), or it may present as an isolated disorder.
This report provides the current prevalent population for Addison’s disease across 10 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, and Poland) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Addison’s have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Addison’s disease include:
• Autoimmune Thyroiditis (AT)
• Type 1 diabetes (T1D)
• Anaemia
• Vitiligo
• Chronic Fatigue
• Premature Ovarian Failure
Hypopigmentation
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Addison’s disease’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Addison’s disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Addison’s disease’s prevalent population.
• Identify sub-populations within Addison’s disease which require treatment.
• Gain an understanding of the specific markets that have the largest number of Addison’s disease patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions/ Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Prevalence for Addison’s Disease
• Main Complications and Features of Addison’s Disease Patients
o Classification of Addison’s Disease
o Number of concomitant conditions in Addison’s Disease
o Co-morbidities within Addison’s disease
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables & Figures
• Prevalence of Addison’s, total (000s)
• Prevalence of Addison’s, males (000s)
• Prevalence of Addison’s, females (000s)
• Addison’s patients by type, total (000s)
• Addison’s patients by number of concomitant conditions, total (000s)
• Addison’s patients with Autoimmune Thyroiditis (AT), total (000s)
• Addison’s patients with T1D, total (000s)
• Addison’s patients with Chronic Fatigue, total (000s)
• Addison’s patients with Anaemia, total (000s)
• Addison’s patients with Vitiligo, total (000s)
• Abbreviations and Acronyms used in the Report
• USA Prevalence of Addison’s disease by 5-yr age cohort, males (000s)
• USA Prevalence of Addison’s disease by 5-yr age cohort, females (000s)
• France Prevalence of Addison’s disease by 5-yr age cohort, males (000s)
• France Prevalence of Addison’s disease by 5-yr age cohort, females (000s)
• Germany Prevalence of Addison’s disease by 5-yr age cohort, males (000s)
• Germany Prevalence of Addison’s disease by 5-yr age cohort, females (000s)
• Italy Prevalence of Addison’s disease by 5-yr age cohort, males (000s)
• Italy Prevalence of Addison’s disease by 5-yr age cohort, females (000s)
• Spain Prevalence of Addison’s disease by 5-yr age cohort, males (000s)
• Spain Prevalence of Addison’s disease by 5-yr age cohort, females (000s)
• United Kingdom Prevalence of Addison’s disease by 5-yr age cohort, males (000s)
• United Kingdom Prevalence of Addison’s disease by 5-yr age cohort, females (000s)
• Brazil Prevalence of Addison’s disease by 5-yr age cohort, males (000s)
• Brazil Prevalence of Addison’s disease by 5-yr age cohort, females (000s)
• Japan Prevalence of Addison’s disease by 5-yr age cohort, males (000s)
• Japan Prevalence of Addison’s disease by 5-yr age cohort, females (000s)
• India Prevalence of Addison’s disease by 5-yr age cohort, males (000s)
• India Prevalence of Addison’s disease by 5-yr age cohort, females (000s)
